8 HLA-A2 restricted peptides Vaccine(Ludwig Institute for Cancer Research)(8 HLA-A2 restricted peptides Vaccine(Ludwig Institute for Cancer Research))

概要

基本信息

药物类型

治疗性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

皮肤黑色素瘤肿瘤

原研机构

Ludwig Institute for Cancer Research Ltd.

在研机构-

非在研机构

Ludwig Institute for Cancer Research Ltd.

权益机构-

最高研发阶段终止临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 8 HLA-A2 restricted peptides Vaccine(Ludwig Institute for Cancer Research) 相关的临床试验

NCT00145158

/ Terminated临床1/2期IIT

Phase I/II Study of Immunization With Multiple Peptides Mixed With the Immunological Adjuvant CpG 7909 or Montanide ISA51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma

The purposes of this study are to describe the immune response to individual peptides after immunization with a combination of 8 peptides and CpG 7909 or Montanide ISA51; to determine the safety of the vaccines and; to document the tumor response in patients receiving the vaccines.

开始日期2005-01-01

申办/合作机构

Ludwig Institute for Cancer Research Ltd.

NCT00199836

/ Completed临床1期IIT

A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer Expressing NY-ESO-1 or LAGE-1.

This cancer vaccine research study involves the injection of the NY-ESO-1b peptide along with 2 other agents to help stimulate the immune system. Peptides are small fragments of protein. NY- ESO-1 peptides are normally found in the testis and the placenta. They have also been found on various types of cancer cells. The purpose is to stimulate the immune system to react against the peptides that are found on cancer cells.

开始日期2003-09-03

申办/合作机构

Ludwig Institute for Cancer Research Ltd.

100 项与 8 HLA-A2 restricted peptides Vaccine(Ludwig Institute for Cancer Research) 相关的临床结果

登录后查看更多信息

100 项与 8 HLA-A2 restricted peptides Vaccine(Ludwig Institute for Cancer Research) 相关的转化医学

登录后查看更多信息

100 项与 8 HLA-A2 restricted peptides Vaccine(Ludwig Institute for Cancer Research) 相关的专利（医药）

登录后查看更多信息

100 项与 8 HLA-A2 restricted peptides Vaccine(Ludwig Institute for Cancer Research) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
皮肤黑色素瘤	临床2期	比利时	Ludwig Institute for Cancer Research Ltd.	2005-01-01
肿瘤	临床1期	德国	Ludwig Institute for Cancer Research Ltd.	2003-09-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00145158 (CTgov)	临床1/2期	皮肤黑色素瘤	23	CpG 7909 (Cohort 1: 8 HLA-A2-restricted Peptides and CpG 7909)	襯選選蓋構獵鬱淵鏇憲 = 積憲願憲醖壓醖衊簾壓鹹願艱醖鏇窪憲壓廠鬱 (齋顧鏇簾糧醖膚齋憲鬱, 獵遞醖顧築鏇憲選鏇膚 ~ 糧窪醖艱醖糧鬱糧膚衊) 更多	-	2022-04-07
NCT00145158 (CTgov)	临床1/2期	皮肤黑色素瘤	23	8 HLA-A2-restricted peptides and Montanide ISA51 (Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51)	襯選選蓋構獵鬱淵鏇憲 = 鑰膚鏇鑰鏇網範蓋範淵鹹願艱醖鏇窪憲壓廠鬱 (齋顧鏇簾糧醖膚齋憲鬱, 願醖積廠鹽壓構簾簾願 ~ 鏇鬱鑰網襯遞獵鏇積窪) 更多	-	2022-04-07
NCT00199836 (CTgov)	临床1期	肿瘤	14	NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51	膚鹽繭鏇壓選廠艱餘窪 = 鑰願簾獵鬱獵鑰鑰選積鬱繭糧鑰窪觸積積膚選 (遞築簾製鑰觸衊壓淵範, 鏇艱餘觸積範製齋鏇製 ~ 鹹蓋構獵築壓顧製構製) 更多	-	2021-07-15